Gene editing of PKLR gene in human hematopoietic progenitors through 5' and 3' UTR modified TALEN mRNA
Quintana-Bustamante, Oscar (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Fañanas-Baquero, S. (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Orman, I. (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Torres, Raul (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Duchateau, P. (CELLECTIS)
Poirot, L. (CELLECTIS)
Gouble, A. (CELLECTIS)
Bueren, Juan (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Segovia, J. C. (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Universitat Autònoma de Barcelona

Date:	2019
Abstract:	Pyruvate Kinase Deficiency (PKD) is a rare erythroid metabolic disease caused by mutations in the PKLR gene, which encodes the erythroid specific Pyruvate Kinase enzyme. Erythrocytes from PKD patients show an energetic imbalance and are susceptible to hemolysis. Gene editing of hematopoietic stem cells (HSCs) would provide a therapeutic benefit and improve safety of gene therapy approaches to treat PKD patients. In previous studies, we established a gene editing protocol that corrected the PKD phenotype of PKD-iPSC lines through a TALEN mediated homologous recombination strategy. With the goal of moving toward more clinically relevant stem cells, we aim at editing the PKLR gene in primary human hematopoietic progenitors and hematopoietic stem cells (HPSCs). After nucleofection of the gene editing tools and selection with puromycin, up to 96% colony forming units showed precise integration. However, a low yield of gene edited HPSCs was associated to the procedure. To reduce toxicity while increasing efficacy, we worked on i) optimizing gene editing tools and ii) defining optimal expansion and selection times. Different versions of specific nucleases (TALEN and CRISPR-Cas9) were compared. TALEN mRNAs with 5' and 3' added motifs to increase RNA stability were the most efficient nucleases to obtain high gene editing frequency and low toxicity. Shortening ex vivo manipulation did not reduce the efficiency of homologous recombination and preserved the hematopoietic progenitor potential of the nucleofected HPSCs. Lastly, a very low level of gene edited HPSCs were detected after engraftment in immunodeficient (NSG) mice. Overall, we showed that gene editing of the PKLR gene in HPSCs is feasible, although further improvements must to be done before the clinical use of the gene editing to correct PKD. Institutode Investigacio ' n Sanitaria de la Fundacio ' n.
Grants:	Ministerio de Economía y Competitividad SAF2017-84248-P Instituto de Salud Carlos III RD16-0011-0011
Note:	Altres ajuts: FEDER/RD16/0011/0011
Note:	Altres ajuts: FEDER/SAF2017-84248-P
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	3' Untranslated Regions ; 5' Untranslated Regions ; Animals ; Cells, Cultured ; Gene Editing ; HEK293 Cells ; Hematopoietic Stem Cells ; Humans ; Mice ; Pyruvate Kinase ; Transcription Activator-Like Effector Nucleases
Published in:	PloS one, Vol. 14 Núm. 10 (january 2019) , p. e0223775, ISSN 1932-6203

DOI: 10.1371/journal.pone.0223775
PMID: 31618280

20 p, 2.3 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles